tiprankstipranks
Neurosense Therapeutics Ltd. (NRSN)
NASDAQ:NRSN
US Market

Neurosense Therapeutics Ltd. (NRSN) Income Statement

65 Followers

Neurosense Therapeutics Ltd. Income Statement

Last quarter (Q4 2022), Neurosense Therapeutics Ltd.'s total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Neurosense Therapeutics Ltd.'s net income was $―. See Neurosense Therapeutics Ltd.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19
Total Revenue
---$ 0.00$ 0.00
Cost of Revenue
-$ -77.00K$ -19.00K--
Gross Profit
-$ 77.00K$ 19.00K--
Operating Expense
$ 10.17M$ 13.55M$ 6.77M$ 2.89M$ 1.24M
Operating Income
$ -10.17M$ -13.55M$ -6.77M$ -2.89M$ -1.24M
Net Non Operating Interest Income Expense
$ 983.00K$ 1.26M$ 2.73M$ -1.00K$ 13.00K
Other Income Expense
-$ 45.00K-$ 61.00K-
Pretax Income
$ -9.19M$ -12.34M$ -4.04M$ -2.83M$ -1.22M
Tax Provision
-----
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -9.19M$ -12.34M$ -4.04M$ -2.83M$ -1.22M
Basic EPS
$ -0.80$ -1.07$ -0.65$ -0.26$ -0.11
Diluted EPS
$ -0.80$ -1.07$ -0.65$ -0.26$ -0.11
Basic Average Shares
$ 34.18M$ 11.53M$ 6.22M$ 10.94M$ 10.94M
Diluted Average Shares
$ 34.18M$ 11.53M$ 6.22M$ 10.94M$ 10.94M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 10.17M$ 13.47M$ 6.75M$ 2.89M$ 1.24M
Net Income From Continuing And Discontinued Operation
$ -9.19M$ -12.34M$ -4.04M$ -2.83M$ -1.22M
Normalized Income
$ -9.19M--$ -2.89M$ -1.22M
Interest Expense
$ 68.00K--$ 1.00K$ 5.00K
EBIT
$ -9.12M$ -12.34M$ -4.04M$ -2.89M$ -1.22M
EBITDA
$ -9.12M$ -12.25M$ -4.04M$ -2.88M$ -1.22M
Currency in USD

Neurosense Therapeutics Ltd. Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis